• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Despite adverse events, corticosteroids may benefit patients with IgA nephropathy

byDaniel FisherandMichael Milligan
August 4, 2017
in Chronic Disease, Nephrology, Urology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this multicenter, double blind study, IgA nephropathy patients had improved kidney function with corticosteroid treatment compared to those treated with placebo.

2. Unfortunately, patients receiving corticosteroids had high rates of serious adverse events, primarily infections, and recruitment for the trial was stopped early.

Evidence Rating Level: 1 (Excellent)

Study Rundown: IgA nephropathy is the most common primary glomerular disease, with highest prevalence in the Asia-Pacific region. Though the disease is mediated by immunoglobulin deposits, validating the use of corticosteroids has been difficult. In this multicenter, double blind study, patients with high risk IgA nephropathy received either full-dose corticosteroids or placebo for 6-8 months and were followed every 3 months for the first year and every 12 months thereafter. After roughly 3 years, the study was discontinued due to a high rate of serious adverse effects—primarily infections—in the corticosteroid group. Though truncated, the study demonstrated that patients who received corticosteroids had better eGFR preservation, and reduced proteinuria compared to those who took placebo.

Though limited, this study adds evidence that high-dose corticosteroids may benefit patients with IgA nephropathy. However, the clear disadvantages of corticosteroid therapy reported in this study make the decision to use this therapy more difficult. Future clinical trials with prophylactic anti-microbials or increased monitoring for immunosuppression-related adverse effects should be undertaken to help physicians decide if and when this regimen should be used for patient with IgA nephropathy.

Click to read the study, published in JAMA

Relevant Reading: Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis

RELATED REPORTS

Germline mutations in CIDEB confer protection from liver disease

Methamphetamine use associated with cardiovascular disease in hospitalized patients

2 Minute Medicine Rewind August 8, 2022

In-Depth [randomized controlled trial]: A total of 262 (86% completing treatment) IgA nephropathy patients with proteinuria >1g/d from China and Australia were randomized to receive full-dose methylprednisolone or placebo daily for 6-8 months and were followed every 3 months for the first year and every 12 months thereafter as part of the Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study. After about 3 years, the study was discontinued due to a statistically significant higher rate of serious adverse effects, primarily infections, in the corticosteroid group (relative risk 4.63 CI95 1.63 to 13.2). Most of these events occurred within the first 3 months of treatment. The primary endpoint was development of a “composite renal outcome,” which consisted of a first occurrence of a 40% decrease in eGFR, the development of ESKD, or death due to kidney disease. Patients who received corticosteroids had a lower rate of this primary renal outcome (Hazard Ratio 0.37; CI95 0.17 to 0.85). The mean annual rate of eGFR decline was less in the corticosteroid treated group (difference of 5.15 mL/min/1.73 m2 ; CI95 0.42 to 9.89 mL/min/1.73 m2. Mean proteinuria was also reduced in the corticosteroid treated group by 0.99 g/d (CI95 −1.34 to −0.64 g/d).

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: nephrology
Previous Post

Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection

Next Post

First-line use of contact aspiration not superior to stent retriever for acute ischemic stroke

RelatedReports

Maternal cell-free DNA sequencing superior to standard aneuploidy screening [CARE Study]
Chronic Disease

Germline mutations in CIDEB confer protection from liver disease

August 9, 2022
Carbon nanotubes ameliorate methamphetamine addiction in mice [PreClinical]
Cardiology

Methamphetamine use associated with cardiovascular disease in hospitalized patients

August 8, 2022
Primary care physicians play substantial role in pediatric mental health
Weekly Rewinds

2 Minute Medicine Rewind August 8, 2022

August 8, 2022
Significant reduction in prostate screening rates after revised guidelines
Chronic Disease

Discrepancies exist between measured and estimated glomerular filtration rate

July 18, 2022
Next Post
Intensive rehabilitation not superior to traditional therapy for arm function after stroke

First-line use of contact aspiration not superior to stent retriever for acute ischemic stroke

Features predicting treatment failure in acute otitis media

Features predicting treatment failure in acute otitis media

Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

2 Minute Medicine Rewind August 7, 2017

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer
  • Tiotropium bromide safe and effective in treating early childhood wheezing
  • Combination mammography and breast tomosynthesis improves breast cancer screening [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.